ATM and pancreatic neoplasm: As a result, the use of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP), previously approved by the Food and Drug Administration (FDA) for treating breast, ovarian, and pancreatic cancers harboring BRCA1 or BRCA2 variants, was, very recently, extended to treat mCRPC patients with deleterious or suspected deleterious germline/somatic alterations in any of 14 HR genes (ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L), who have progressed following prior treatment with second-generation ADT therapy.